Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 10/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944845 | 0.95 | ALOX15 (0.44) | ALOX15CA2EZH2FUCA1ALDH1A1 | |
| SCHEMBL9944996 | 0.87 | EZH2 (0.37) | ALOX15CA2EZH2ALDH1A1MAPT | |
| SCHEMBL9946642 | 0.86 | PTGES (0.42) | EZH2PRKCIPTGES | |
| SCHEMBL9946614 | 0.82 | PTGES (0.44) | ALOX15EZH2ALDH1A1MAPTNPSR1 | |
| SCHEMBL9944838 | 0.81 | ALDH1A1 (0.39) | CA2ALDH1A1MAPTNPSR1 | |
| SCHEMBL9946863 | 0.81 | PTGES (0.45) | EZH2ALDH1A1MAPTNPSR1PTGES | |
| SCHEMBL9944853 | 0.80 | ALOX15 (0.34) | ALOX15PRKCIALDH1A1MAPT | |
| SCHEMBL9944844 | 0.78 | ALDH1A1 (0.45) | CA2EZH2ALDH1A1MAPTNPSR1 | |
| SCHEMBL9944904 | 0.77 | RAB9A (0.44) | — | |
| SCHEMBL9946636 | 0.74 | PTGES (0.44) | ALDH1A1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALOX15 106/4885CA2 2940/4885EZH2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.